I. , E. Du, and .. De-prostate-et-du-psa, 62 II.3.1 Vision d'ensemble: ce qu'il faut savoir, p.73

T. Henry, Diseases of the Prostate: Their Pathology and Treatment

T. Stamey, Y. N. Hay, A. Mcneal, J. Freiha, F. Redwine et al., Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate, New England Journal of Medicine, vol.317, issue.15, pp.909-916, 1987.
DOI : 10.1056/NEJM198710083171501

A. Gutman and E. Gutman, AN ??? ACID ??? PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND, Journal of Clinical Investigation, vol.17, issue.4, pp.473-478, 1938.
DOI : 10.1172/JCI100974

E. Gutman, E. Sproul, and A. Gutman, Significance of increase phosphatase activity of bone at the site of osteoplastic metastasis secondary to carcinoma of the prostate gland, Am J Cancer, p.28485, 1936.

F. Milgrom, Z. Tuggac, and E. Witebsky, Organ-specific antigens of liver, testicle and pituitary, J. Immunol, vol.94, pp.157-163, 1965.

T. Edgington, R. Glassock, J. Watson, and F. Dixon, Characterization and isolation of specific renal tubular epithelial antigens, J. Immunol. Déc, vol.99, issue.6, pp.1199-1210, 1967.

R. Flocks, V. Urich, C. Patel, and J. Opitz, Studies on the Antigenic Properties of Prostatic Tissue I., The Journal of Urology, vol.84, issue.1, pp.134-143, 1960.
DOI : 10.1016/S0022-5347(17)65503-4

R. Flocks, K. Bandhaur, C. Patel, and B. Begley, Studies on Spermagglutinating Antibodies in Antihuman Prostate Sera, The Journal of Urology, vol.87, issue.3, pp.475-478, 1962.
DOI : 10.1016/S0022-5347(17)64982-6

R. Ablin, L. Pfeiffer, M. Gonder, and W. Soanes, Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate, Exp Med Surg, vol.27, issue.4, pp.406-410, 1969.

R. Ablin, P. Bronson, W. Soanes, and E. Witebsky, Tissue-and species-specific antigens of normal human prostatic tissue, J. Immunol, vol.104, issue.6, pp.1329-1339, 1970.

R. Ablin, W. Soanes, P. Bronson, and E. Witebsky, PRECIPITATING ANTIGENS OF THE NORMAL HUMAN PROSTATE, Reproduction, vol.22, issue.3, pp.573-574, 1970.
DOI : 10.1530/jrf.0.0220573

R. Ablin, Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer, pp.1570-1574, 1972.

M. Hara, Y. Koyanagi, T. Inoue, and T. Fukuyama, Some physico-chemical characteristics of " seminoprotein" , an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII], Nihon Hoigaku Zasshi, 1971.

J. Zorn and M. Svala, Stérilité du couple. 2 éd, 2005.

T. Li and S. Behrman, The Sperm- and Seminal Plasma-Specific Antigens of Human Semen**Supported by Ford Foundation Grant 37482., Fertility and Sterility, vol.21, issue.7, pp.565-573, 1970.
DOI : 10.1016/S0015-0282(16)37627-0

T. Li and C. Beling, Isolation and characterization of two specific antigens of human seminal plasma, Fertil. Steril. Fév, vol.24, issue.2, pp.134-144, 1973.

L. Sokoll and D. Chan, PROSTATE-SPECIFIC ANTIGEN, Urologic Clinics of North America, vol.24, issue.2, pp.253-259, 1997.
DOI : 10.1016/S0094-0143(05)70370-0

G. Sensabaugh, Isolation and Characterization of a Semen-Specific Protein from Human Seminal Plasma: A Potential New Marker for Semen Identification, Journal of Forensic Sciences, vol.23, issue.1, pp.106-115, 1978.
DOI : 10.1520/JFS10659J

M. Wang, L. Valenzuela, G. Murphy, and T. Chu, Purification of a human prostate specific antigen, The Journal of Urology, vol.167, issue.2, pp.159-163, 1979.
DOI : 10.1016/S0022-5347(02)80311-1

L. Papsidero, M. Wang, L. Valenzuela, G. Murphy, and T. Chu, A prostate antigen in sera of prostatic cancer patients, Cancer Res, vol.40, issue.7, pp.2428-2432, 1980.

M. Kuriyama, M. Wang, L. Papsidero, C. Killian, T. Shimano et al., Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay, Cancer Res. Déc, vol.40, issue.12, pp.4658-4662, 1980.

M. Wang, L. Papsidero, M. Kuriyama, L. Valenzuela, G. Murphy et al., Prostate antigen: A new potential marker for prostatic cancer, The Prostate, vol.40, issue.1, pp.89-96, 1981.
DOI : 10.1002/pros.2990020109

M. Wang, L. Papsidero, and T. Chu, Prostate-specific antigen, p30, ??-seminoprotein, and EI, The Prostate, vol.66, issue.2, pp.107-110, 1994.
DOI : 10.1111/j.1432-1033.1987.tb13674.x

A. Christensson, C. Laurell, and H. Lilja, Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors, European Journal of Biochemistry, vol.40, issue.3, pp.755-763, 1990.
DOI : 10.1016/0304-4165(83)90096-X

H. Lilja, A. Christensson, U. Dahlén, M. Matikainen, O. Nilsson et al., Prostatespecific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin, Clin. Chem, vol.37, issue.9, pp.1618-1625, 1991.

U. Stenman, J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen et al., A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer, Cancer Res, vol.51, issue.1, pp.222-226, 1991.

H. Lilja, Structure and function of prostatic-and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen. Scand, J. Clin. Lab. Invest, vol.191, pp.13-20, 1988.

A. Herrala, R. Kurkela, K. Porvari, R. Isomäki, P. Henttu et al., Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein, Clin. Chem, 1997.

J. Finlay, J. Day, and H. Rittenhouse, Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1, Urology, vol.53, issue.4, 1999.
DOI : 10.1016/S0090-4295(98)00573-1

T. Takayama, K. Fujikawa, and E. Davie, Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein, J. Biol. Chem. Aoû, vol.22272, issue.34, pp.21582-21588, 1997.

A. Kumar, S. Mikolajczyk, A. Goel, L. Millar, and M. Saedi, Expression of pro form of prostatespecific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res, Aoû, vol.157, issue.15, pp.3111-3114, 1997.

J. Lövgren, K. Rajakoski, M. Karp, . Lundwall-Â, and H. Lilja, Activation of the Zymogen Form of Prostate-Specific Antigen by Human Glandular Kallikrein 2, Biochemical and Biophysical Research Communications, vol.238, issue.2, pp.549-555, 1997.
DOI : 10.1006/bbrc.1997.7333

C. Huggins and W. Neal, COAGULATION AND LIQUEFACTION OF SEMEN: PROTEOLYTIC ENZYMES AND CITRATE IN PROSTATIC FLUID, Journal of Experimental Medicine, vol.76, issue.6, pp.527-541, 1942.
DOI : 10.1084/jem.76.6.527

T. Klokk, A. Kilander, Z. Xi, H. Waehre, B. Risberg et al., Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res, pp.5221-5230, 2007.

C. Sävblom, J. Malm, A. Giwercman, J. Nilsson, G. Berglund et al., Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age, The Prostate, vol.48, issue.1, pp.66-72, 2005.
DOI : 10.1046/j.1464-410X.1998.00723.x

T. Piironen, M. Nurmi, K. Irjala, O. Heinonen, H. Lilja et al., Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing, Clin. Chem. Avr, vol.47, issue.4, pp.703-711, 2001.

J. Schaller, K. Akiyama, R. Tsuda, M. Hara, T. Marti et al., Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma

H. Frazier, P. Humphrey, J. Burchette, and D. Paulson, Immunoreactive Prostatic Specific Antigen in Male Periurethral Glands, The Journal of Urology, vol.147, issue.1, pp.246-248, 1992.
DOI : 10.1016/S0022-5347(17)37206-3

M. Dodson, W. Cliby, G. Keeney, M. Peterson, and K. Podratz, Skene's Gland Adenocarcinoma with Increased Serum Level of Prostate-Specific Antigen, Gynecologic Oncology, vol.55, issue.2, pp.304-307, 1994.
DOI : 10.1006/gyno.1994.1294

K. Alanen, T. Kuopio, P. Koskinen, and T. Nevalainen, Immunohistochemical Labelling for Prostate Specific Antigen in Non-Prostatic Tissues, Pathology - Research and Practice, vol.192, issue.3, pp.233-237, 1996.
DOI : 10.1016/S0344-0338(96)80226-3

P. Schuff-werner and C. Zingler, Possible value of positive PSA levels in malignant and nonmalignant breast diseases]. Onkologie, Fév, vol.24, issue.1, pp.11-17, 2001.

E. Diamandis, Prostate specific antigen--new applications in breast and other cancers, Anticancer Res. Déc, vol.16, issue.6C, pp.3983-3984, 1996.

J. Oesterling, A. Tekchandani, S. Martin, E. Bergstralh, E. Reichstein et al., The Periurethral Glands do not Significantly Influence the Serum Prostate Specific Antigen Concentration, The Journal of Urology, vol.155, issue.5, pp.1658-1660, 1996.
DOI : 10.1016/S0022-5347(01)66156-1

S. Qiu, C. Young, D. Bilhartz, J. Prescott, G. Farrow et al., In Situ Hybridization of Prostate-Specific Antigen mRNA in Human Prostate, The Journal of Urology, vol.144, issue.6, pp.1550-1556, 1990.
DOI : 10.1016/S0022-5347(17)39797-5

J. Cosset, O. Cussenot, and F. Haab, Le cancer de la prostate: Prise en charge de la maladie et de ses séquelles, 2007.

H. Lilja, D. Ulmert, and A. Vickers, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring, Nature Reviews Cancer, vol.174, issue.4, pp.268-278, 2008.
DOI : 10.1016/j.urolonc.2005.11.039

D. Angelis, G. Rittenhouse, H. Mikolajczyk, S. , B. Shamel et al., Twenty Years of PSA: From Prostate Antigen to Tumor Marker, Rev Urol, vol.9, issue.3, pp.113-123, 2007.

H. Graves, N. Wehner, and T. Stamey, Ultrasensitive radioimmunoassay of prostate-specific antigen, Clin. Chem. Mai, vol.38, issue.5, pp.735-742, 1992.

T. Stamey, H. Graves, N. Wehner, M. Ferrari, and F. Freiha, Early Detection of Residual Prostate Cancer After Radical Prostatectomy by an Ultrasensitive Assay for Prostate Specific Antigen, The Journal of Urology, vol.149, issue.4, pp.787-792, 1993.
DOI : 10.1016/S0022-5347(17)36208-0

F. Desgrandchamps and P. Teillac, Que peut attendre le clinicien aujourd'hui du dosage du PSA ?, Immuno-analyse & Biologie Sp??cialis??e, vol.8, issue.4, pp.234-243, 1993.
DOI : 10.1016/S0923-2532(05)80006-7

G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1042/bj1280427

K. Rajakoski, T. Piironen, K. Pettersson, J. Lövgren, and M. Karp, Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells. Prostate Cancer Prostatic Dis, pp.16-20, 1997.

A. Zhou, P. Tewari, B. Bluestein, G. Caldwell, and F. Larsen, Multiple forms of prostatespecific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays, Clin. Chem. Déc, vol.39, issue.12, pp.2483-2491, 1993.

C. Tillyer, M. Konings, P. Gobin, and J. Iqbal, Disagreement between the Roche Cobas(R) Core and Hybritech TANDEM(R)-E PSA Assays When Measuring Free, Complexed and Total Serum Prostate Specific Antigen, Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine, vol.31, issue.5, pp.501-505, 1994.
DOI : 10.1177/000456329403100514

W. Catalona, D. Smith, T. Ratliff, K. Dodds, D. Coplen et al., Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer, New England Journal of Medicine, vol.324, issue.17, 1991.
DOI : 10.1056/NEJM199104253241702

W. Catalona, M. Hudson, P. Scardino, J. Richie, F. Ahmann et al., Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves, The Journal of Urology, vol.152, issue.6, pp.2037-2042, 1994.
DOI : 10.1016/S0022-5347(17)32300-5

T. Stamey, Second stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994, Urology, vol.45, issue.2, pp.173-184, 1994.
DOI : 10.1016/0090-4295(95)80001-8

G. Sölétormos, A. Semjonow, P. Sibley, R. Lamerz, P. Petersen et al., Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice, Clinical Chemistry, vol.51, issue.8, pp.1342-1351, 2005.
DOI : 10.1373/clinchem.2004.046086

W. Catalona, C. Ramos, G. Carvalhal, and Y. Yan, Lowering PSA cutoffs to enhance detection of curable prostate cancer, Urology, vol.55, issue.6, pp.791-795, 2000.
DOI : 10.1016/S0090-4295(99)00602-0

A. Berger, H. Volgger, H. Rogatsch, D. Strohmeyer, H. Steiner et al., Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens, The Prostate, vol.164, issue.3, pp.241-245, 2002.
DOI : 10.1016/S0022-5347(05)67456-3

R. Punglia, D. Amico, A. Catalona, W. Roehl, K. Kuntz et al., Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen, New England Journal of Medicine, vol.349, issue.4, 2003.
DOI : 10.1056/NEJMoa021659

I. Thompson, D. Pauler, P. Goodman, C. Tangen, M. Lucia et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4

U. Stenman, M. Hakama, P. Knekt, A. Aromaa, L. Teppo et al., Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer, Lancet. Déc, vol.10344, issue.8937, pp.1594-1598, 1994.

P. Gann, C. Hennekens, and M. Stampfer, A Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer, JAMA: The Journal of the American Medical Association, vol.273, issue.4, pp.289-294, 1995.
DOI : 10.1001/jama.1995.03520280035036

H. Lilja, D. Ulmert, T. Björk, C. Becker, A. Serio et al., Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years, Journal of Clinical Oncology, vol.25, issue.4, pp.431-436, 2007.
DOI : 10.1200/JCO.2006.06.9351

R. Bailly, Restandardisation OMS des dosages PSA et PSA libre Access hybritech. Clinical News, Avr, issue.13, pp.12-13, 2007.

C. Coulange and J. Davin, Urologie et Cancer, John Libbey Eurotext, 2004.

T. Stamey, J. Kabalin, J. Mcneal, I. Johnstone, F. Freiha et al., Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated Patients, The Journal of Urology, vol.141, issue.5, pp.1076-1083, 1989.
DOI : 10.1016/S0022-5347(17)41175-X

A. Partin, G. Hanks, E. Klein, J. Moul, W. Nelson et al., Prostate-specific antigen as a marker of disease activity in prostate cancer, Oncology, 2002.

A. Caplan and A. Kratz, Prostate-Specific Antigen and the Early Diagnosis of Prostate Cancer, Pathology Patterns Reviews, vol.117, issue.suppl_1, pp.104-108, 2002.
DOI : 10.1309/C4UN-12LK-43HP-JXY3

P. Walz, T. Schoppmann, C. Büscher, J. Ennen, and H. Schriewer, Influence of Prostatic Disease and Prostatic Manipulations on the Concentration of Prostate-Specific Antigen, European Urology, vol.22, issue.1, pp.20-26, 1992.
DOI : 10.1159/000474716

J. Yuan, D. Coplen, J. Petros, R. Figenshau, T. Ratliff et al., Effects of Rectal Examination, Prostatic Massage, Ultrasonography and Needle Biopsy on Serum Prostate Specific Antigen Levels, The Journal of Urology, vol.147, issue.3, pp.810-814, 1992.
DOI : 10.1016/S0022-5347(17)37392-5

A. Partin, J. Yoo, H. Carter, J. Pearson, D. Chan et al., The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer, The Journal of Urology, vol.150, issue.1, pp.110-114, 1993.
DOI : 10.1016/S0022-5347(17)35410-1

M. Kattan, J. Eastham, A. Stapleton, T. Wheeler, and P. Scardino, A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer, J. Natl. Cancer Inst Mai, vol.2090, issue.10, pp.766-771, 1998.

D. Amico and A. , Combined-modality staging for localized adenocarcinoma of the prostate, Oncology Aoû, vol.15, issue.8, pp.1049-1059, 1060.

F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto et al., Screening and Prostate-Cancer Mortality in a Randomized European Study, New England Journal of Medicine, vol.360, issue.13, pp.1320-1328, 2009.
DOI : 10.1056/NEJMoa0810084

K. Mistry and G. Cable, Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma, The Journal of the American Board of Family Medicine, vol.16, issue.2, pp.95-101, 2003.
DOI : 10.3122/jabfm.16.2.95

W. Catalona, J. Richie, J. Dekernion, F. Ahmann, T. Ratliff et al., Comparison of Prostate Specific Antigen Concentration Versus Prostate Specific Antigen Density in the Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves, The Journal of Urology, vol.152, issue.6, pp.2031-2036, 1994.
DOI : 10.1016/S0022-5347(17)32299-1

W. Catalona, A. Partin, J. Finlay, D. Chan, H. Rittenhouse et al., Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model, Urology, vol.54, issue.2, pp.220-224, 1999.
DOI : 10.1016/S0090-4295(99)00185-5

B. Djavan, A. Zlotta, C. Kratzik, M. Remzi, C. Seitz et al., PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL, Urology, vol.54, issue.3, pp.517-522, 1999.
DOI : 10.1016/S0090-4295(99)00153-3

R. Babaian, H. Fritsche, A. Ayala, V. Bhadkamkar, D. Johnston et al., Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL, Urology, vol.56, issue.6, pp.1000-1006, 2000.
DOI : 10.1016/S0090-4295(00)00830-X

W. Catalona, D. Smith, and D. Ornstein, Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements, JAMA: The Journal of the American Medical Association, vol.277, issue.18, pp.1452-1455, 1997.
DOI : 10.1001/jama.277.18.1452

M. Lucia, A. Darke, P. Goodman, L. Rosa, F. Parnes et al., Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention, Cancer Prevention Research, vol.1, issue.3, pp.167-173, 2008.
DOI : 10.1158/1940-6207.CAPR-08-0078

R. Smith, A. Eschenbach, R. Wender, B. Levin, T. Byers et al., American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection, CA: A Cancer Journal for Clinicians, vol.51, issue.1, pp.38-75, 2001.
DOI : 10.3322/canjclin.51.1.38

K. Verhamme, J. Dieleman, G. Bleumink, J. Van-der-lei, M. Sturkenboom et al., Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care???The Triumph Project, European Urology, vol.42, issue.4, pp.323-328, 2002.
DOI : 10.1016/S0302-2838(02)00354-8

J. Oesterling, S. Jacobsen, G. Klee, K. Pettersson, T. Piironen et al., Free, Complexed and Total Serum Prostate Specific Antigen, The Journal of Urology, vol.154, issue.3, pp.1090-1095, 1995.
DOI : 10.1097/00005392-199509000-00051

T. Morgan, S. Jacobsen, W. Mccarthy, D. Jacobson, D. Mcleod et al., Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men, New England Journal of Medicine, vol.335, issue.5, pp.304-310, 1996.
DOI : 10.1056/NEJM199608013350502

W. Catalona, P. Southwick, K. Slawin, A. Partin, M. Brawer et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, Urology, vol.56, issue.2, pp.255-260, 2000.
DOI : 10.1016/S0090-4295(00)00637-3

H. Carter, C. Morrell, J. Pearson, L. Brant, C. Plato et al., Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease, Cancer Res, vol.52, issue.12, pp.3323-3328, 1992.

H. Carter, J. Pearson, E. Metter, L. Brant, D. Chan et al., Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease, JAMA. Avr, vol.22267, issue.16, pp.2215-2220, 1992.

D. Ulmert, A. Serio, O. Brien, M. Becker, C. Eastham et al., Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population, Journal of Clinical Oncology, vol.26, issue.6, pp.835-841, 2008.
DOI : 10.1200/JCO.2007.13.1490

I. Thompson, D. Ankerst, C. C. Goodman, P. Tangen, C. Lucia et al., Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial, JNCI: Journal of the National Cancer Institute, vol.98, issue.8, 2006.
DOI : 10.1093/aje/kwh101

A. Christensson, T. Björk, O. Nilsson, U. Dahlén, M. Matikainen et al., Serum Prostate Specific Antigen Complexed to ?? 1-Antichymotrypsin as an Indicator of Prostate Cancer, The Journal of Urology, vol.150, issue.1, pp.100-105, 1993.
DOI : 10.1016/S0022-5347(17)35408-3

W. Catalona, A. Partin, K. Slawin, M. Brawer, R. Flanigan et al., Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA Mai, vol.20279, pp.1542-1547, 1998.

W. Catalona, G. Bartsch, H. Rittenhouse, C. Evans, H. Linton et al., Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/Ml, The Journal of Urology, vol.170, issue.6, pp.2181-2185, 2003.
DOI : 10.1097/01.ju.0000095460.12999.43

S. Mikolajczyk, W. Catalona, C. Evans, H. Linton, L. Millar et al., Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer, Clinical Chemistry, vol.50, issue.6, pp.1017-1025, 2004.
DOI : 10.1373/clinchem.2003.026823

P. Nurmikko, K. Pettersson, T. Piironen, J. Hugosson, and H. Lilja, Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146, Clin. Chem. Aoû, vol.47, issue.8, pp.1415-1423, 2001.

Y. Fulla, M. Noel, L. Brun, and G. , Optimisation de l'utiisation du PSA. Med Nuc, pp.31-40, 2007.
DOI : 10.1016/j.mednuc.2007.11.004

L. Eurostaf-groupe and . Echos, Les perspectives des laboratoires d'analyse médicale à l'horizon 2012, 2008.

N. Henry, P. Sebe, and O. Cussenot, Inappropriate treatment of prostate cancer caused by heterophilic antibody interference, Nature Clinical Practice Urology, vol.180, issue.3, pp.164-167, 2009.
DOI : 10.1093/ajcp/108.4.417

H. Young and . Xv, CANCER OF THE PROSTATE. A CLINICAL, PATHOLOGICAL AND POST-OPERATIVE ANALYSIS OF III CASES, Annals of Surgery, vol.50, issue.6, pp.1144-1233, 1909.
DOI : 10.1097/00000658-190912000-00015

URL : https://hal.archives-ouvertes.fr/hal-00510976

L. Michel, La chirurgie du temps jadis, Cancer Info, issue.58, p.13, 1999.

H. Conseil-de-la-santé-publique, Evaluation du plan cancer 2003-2007. Rapport final, 2009.

C. Fancesconi and R. Launois, Evaluation du coût du dépistage organisé du cancer colorectal et du cancer du sein, 2007.

S. Shapiro, P. Strax, and L. Venet, Evaluation of periodic breast cancer screening with mammography. Methodology and early observations, JAMA: The Journal of the American Medical Association, vol.195, issue.9, pp.731-738, 1966.
DOI : 10.1001/jama.195.9.731

G. Howe, G. Sherman, R. Semenciw, and A. Miller, Estimated benefits and risks of screening for breast cancer, Can Med Assoc J. Fév, vol.15124, issue.4, pp.399-403, 1981.

S. Shapiro, W. Venet, P. Strax, L. Venet, and R. Roeser, Ten-to fourteen-year effect of screening on breast cancer mortality, J. Natl. Cancer Inst. Aoû, vol.69, issue.2, pp.349-355, 1982.

J. Mandel, J. Bond, T. Church, D. Snover, G. Bradley et al., Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N. Engl. J. Med. Mai, vol.13328, pp.1365-1371, 1993.

J. Hardcastle, J. Chamberlain, M. Robinson, S. Moss, S. Amar et al., Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 1996.

L. Koutsky, K. Ault, C. Wheeler, D. Brown, E. Barr et al., A Controlled Trial of a Human Papillomavirus Type 16 Vaccine, New England Journal of Medicine, vol.347, issue.21, pp.1645-1651, 2002.
DOI : 10.1056/NEJMoa020586

D. Harper, E. Franco, C. Wheeler, D. Ferris, D. Jenkins et al., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, The Lancet, vol.364, issue.9447, pp.1757-1765, 2004.
DOI : 10.1016/S0140-6736(04)17398-4

J. Wilson and Y. Jungner, [Principles and practice of mass screening for disease], Bol Oficina Sanit Panam, vol.65, issue.4, pp.281-393, 1968.

J. Blay, F. Eisinger, O. Rixe, A. Calazel-benque, J. Morère et al., Edifice program: analysis of screening exam practices for cancer in France]. Bull Cancer, pp.1067-1073, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00483422

B. Paul, Le gouffre du cancer de la prostate. LeMonde.fr, 2010.

R. Ablin and M. Haythorn, Prostate cancer screening, The Lancet, vol.357, issue.9263, pp.1-2, 2009.
DOI : 10.1016/S0140-6736(00)04341-5

T. Stamey, The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA, BJU International, vol.163, issue.7, pp.963-964, 2004.
DOI : 10.1097/00005392-200107000-00021

J. Johansson, H. Adami, S. Andersson, R. Bergström, U. Krusemo et al., Natural history of localised prostatic cancer. A population-based study in 223 untreated patients, Lancet, 1989.

H. Lepor and P. Walsh, Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital, NCI Monogr, issue.7, pp.117-122, 1988.

. Le-dépistage-du-cancer-localisé-de-la-prostate, Rapport de la première Conférence de Consensus, 1989.

G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia et al., Mortality Results from a Randomized Prostate-Cancer Screening Trial, New England Journal of Medicine, vol.360, issue.13, pp.1310-1319, 2009.
DOI : 10.1056/NEJMoa0810696

A. Nationale-d, Evaluation et d'Accréditation en Santé. Opportunité d'un dépistage systématique du cancer de la prostate par le dosage de l'antigène spécifique de la prostate, 1999.

A. Farkas, D. Schneider, M. Perrotti, K. Cummings, and W. Ward, National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening, Urology, vol.52, issue.3, pp.444-448, 1973.
DOI : 10.1016/S0090-4295(98)00242-8

F. Labrie, B. Candas, A. Dupont, L. Cusan, J. Gomez et al., Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial, The Prostate, vol.80, issue.2, pp.83-91, 1999.
DOI : 10.1016/S0022-5347(01)67074-5

R. Roberts, E. Bergstralh, S. Katusic, M. Lieber, and S. Jacobsen, Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County

B. Hankey, E. Feuer, L. Clegg, R. Hayes, J. Legler et al., Cancer Surveillance Series: Interpreting Trends in Prostate Cancer??Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates, JNCI Journal of the National Cancer Institute, vol.13, issue.1, pp.1017-1024, 1999.
DOI : 10.2165/00002512-199813010-00007

M. Cookson, Prostate cancer: screening and early detection. Cancer Control, 2001.

G. Bartsch, W. Horninger, H. Klocker, A. Reissigl, W. Oberaigner et al., Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria, Urology, vol.58, issue.3, pp.417-424, 2001.
DOI : 10.1016/S0090-4295(01)01264-X

P. Walsh and J. Mostwin, Radical Prostatectomy and Cystoprostatectomy with Preservation of Potency. Results Using a New Nerve-sparing Technique, British Journal of Urology, vol.4, issue.Supplement 7, pp.694-697, 1984.
DOI : 10.1001/archneurpsyc.1939.02270210041003

M. Soulié, C. Barré, P. Beuzeboc, D. Chautard, F. Cornud et al., Cancer de la prostate: Recommandations du CCAFU, Prog. Urol, vol.14, issue.4, pp.913-915, 2004.

M. Soulié, P. Beuzeboc, F. Cornud, P. Eschwège, N. Gaschignard et al., Cancer de la Prostate: recommandations CCAFU, Prog Urol, vol.17, pp.1159-1230, 2007.

A. Nationale-d, Evaluation et d'Accréditation en Santé. Eléments d'information des hommes envisageant la réalisation d'un dépistage individuel du cancer de la prostate, 2004.

A. Communiqué-de-presse-inca and H. , Dépistage du cancer de la prostate: de nouveaux éclairages vont contribuer à la définition de la politique publique à mettre en place, 2009.

M. Peyromaure, P. Beuzeboc, L. Salomon, P. Richaud, P. Coloby et al., Le d??pistage du cancer de la prostate en 2009??: mise au point du comit?? de canc??rologie de l???Association fran??aise d???urologie, Progr??s en Urologie, vol.20, issue.1, pp.17-23, 2010.
DOI : 10.1016/j.purol.2009.09.033

M. Roobol, M. Kerkhof, F. Schröder, J. Cuzick, P. Sasieni et al., Prostate Cancer Mortality Reduction by Prostate-Specific Antigen???Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC), European Urology, vol.56, issue.4
DOI : 10.1016/j.eururo.2009.07.018

M. Coleman, M. Quaresma, F. Berrino, J. Lutz, D. Angelis et al., Cancer survival in five continents: a worldwide population-based study (CONCORD), The Lancet Oncology, vol.9, issue.8, pp.730-756, 2008.
DOI : 10.1016/S1470-2045(08)70179-7

A. Bill-axelson, L. Holmberg, F. Filén, M. Ruutu, H. Garmo et al., Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial, JNCI Journal of the National Cancer Institute, vol.88, issue.17, pp.1144-1154, 2008.
DOI : 10.1093/jnci/88.17.1216

A. Bill-axelson, L. Holmberg, M. Ruutu, M. Häggman, S. Andersson et al., Radical prostatectomy versus watchful waiting in early prostate cancer, N. Engl. J. Med. Mai, vol.12352, pp.1977-1984, 2005.

L. Cormier, Epidémiologie du cancer de la prostate. Dans: Le Cancer de la Prostate, pp.17-29, 2005.

C. Mettlin, G. Jones, H. Averette, S. Gusberg, and G. Murphy, Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers, CA: A Cancer Journal for Clinicians, vol.43, issue.1, pp.42-46, 1993.
DOI : 10.3322/canjclin.43.1.42

W. Catalona, D. Smith, T. Ratliff, and J. Basler, Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening, JAMA. Aoû, vol.25270, issue.8, pp.948-954, 1993.

D. Smith and W. Catalona, The Nature of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening, The Journal of Urology, vol.152, issue.5, pp.1732-1736, 1994.
DOI : 10.1016/S0022-5347(17)32372-8

A. Jemal, R. Tiwari, T. Murray, A. Ghafoor, A. Samuels et al., Cancer Statistics, 2004, CA: A Cancer Journal for Clinicians, vol.54, issue.1, pp.8-29, 2004.
DOI : 10.3322/canjclin.54.1.8

L. Franks, Latent carcinoma of the prostate, The Journal of Pathology and Bacteriology, vol.liii, issue.2, pp.603-616, 1954.
DOI : 10.1001/jama.1947.62890170001007

W. Sakr, G. Haas, B. Cassin, J. Pontes, and J. Crissman, The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients, The Journal of Urology, vol.150, issue.2, pp.379-385, 1993.
DOI : 10.1016/S0022-5347(17)35487-3

M. Sánchez-chapado, G. Olmedilla, M. Cabeza, E. Donat, and A. Ruiz, Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study, The Prostate, vol.73, issue.Suppl, pp.238-247, 2003.
DOI : 10.1002/(SICI)1097-0215(19971210)73:6<808::AID-IJC6>3.0.CO;2-6

K. Stamatiou, A. Alevizos, E. Agapitos, and F. Sofras, Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An autopsy study, The Prostate, vol.83, issue.12, pp.1319-1328, 2006.
DOI : 10.1080/003655900750169257-1

T. Stamey, F. Freiha, J. Mcneal, E. Redwine, A. Whittemore et al., Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, vol.140, issue.S3, pp.933-938, 1993.
DOI : 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L

G. Draisma, R. Boer, S. Otto, I. Van-der-cruijsen, R. Damhuis et al., Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.42, issue.5-7, pp.868-878, 2003.
DOI : 10.1287/mnsc.42.7.954

M. Cooperberg, J. Broering, P. Kantoff, and P. Carroll, Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment, The Journal of Urology, vol.178, issue.3, pp.14-19, 2007.
DOI : 10.1016/j.juro.2007.03.135

F. Chun, N. Suardi, U. Capitanio, C. Jeldres, S. Ahyai et al., Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy, European Urology, vol.55, issue.3, pp.617-628, 2009.
DOI : 10.1016/j.eururo.2008.04.099

L. Salomon, Prostatectomie du cancer de la prostate Intérêt de la laparoscopie par rapport aux voies chirurgicales classiques. Dans: Le Cancer de la Prostate. Ellipses, pp.145-70, 2005.

J. Epstein, P. Walsh, M. Carmichael, and C. Brendler, Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA: The Journal of the American Medical Association, vol.271, issue.5, pp.368-374, 1994.
DOI : 10.1001/jama.271.5.368

C. Warlick, B. Trock, P. Landis, J. Epstein, and H. Carter, Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome, JNCI: Journal of the National Cancer Institute, vol.98, issue.5, pp.355-357, 2006.
DOI : 10.1056/NEJMoa043739

L. Klotz, Active Surveillance for Favorable Risk Prostate Cancer, The Journal of Urology, vol.182, issue.6, pp.692-698, 2007.
DOI : 10.1016/j.juro.2009.09.038

Y. Krakowsky, A. Loblaw, and L. Klotz, Prostate Cancer Death of Men Treated With Initial Active Surveillance: Clinical and Biochemical Characteristics, The Journal of Urology, vol.184, issue.1, p.15, 2010.
DOI : 10.1016/j.juro.2010.03.041

C. Baquet, J. Horm, T. Gibbs, and P. Greenwald, Socioeconomic Factors and Cancer Incidence Among Blacks and Whites, JNCI Journal of the National Cancer Institute, vol.83, issue.8, pp.551-557, 1991.
DOI : 10.1093/jnci/83.8.551

O. Cussenot and G. Cancel-tassin, Genetic Susceptibility to Prostate Cancer, Med Sci, vol.66, issue.2, 2004.
DOI : 10.1016/0140-6736(92)90927-U

A. Azzouzi, D. Stoppa-lyonnet, M. Roupret, S. Larre, P. Mangin et al., BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families, International Journal of Urology, vol.13, issue.5, 2007.
DOI : 10.1038/sj.ejhg.5200988

P. Kupelian, V. Kupelian, J. Witte, R. Macklis, and E. Klein, Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome., Journal of Clinical Oncology, vol.15, issue.4, pp.1478-1480, 1997.
DOI : 10.1200/JCO.1997.15.4.1478

E. Spangler, C. Zeigler-johnson, S. Malkowicz, A. Wein, and T. Rebbeck, Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors, International Journal of Cancer, vol.167, issue.3, pp.471-474, 2005.
DOI : 10.1046/j.1464-410X.1998.00801.x

L. Albright, A. Schwab, N. Camp, J. Farnham, and A. Thomas, Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases, The Prostate, vol.72, issue.4, pp.347-355, 2005.
DOI : 10.1002/pros.20248

C. Jerónimo, H. Usadel, H. R. Oliveira, J. Lopes, C. Nelson et al., Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma, JNCI Journal of the National Cancer Institute, vol.21, issue.4, pp.1747-1752, 2001.
DOI : 10.1016/0090-4295(83)90170-X

B. Laxman, S. Tomlins, R. Mehra, D. Morris, L. Wang et al., Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer, Neoplasia, vol.8, issue.10, pp.885-888, 2006.
DOI : 10.1593/neo.06625

D. Hessels, K. Gunnewiek, J. Van-oort, I. Karthaus, H. Van-leenders et al., DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

P. Zielie, J. Mobley, R. Ebb, Z. Jiang, R. Blute et al., A NOVEL DIAGNOSTIC TEST FOR PROSTATE CANCER EMERGES FROM THE DETERMINATION OF ??-METHYLACYL-COENZYME A RACEMASE IN PROSTATIC SECRETIONS, The Journal of Urology, vol.172, issue.3, pp.1130-1133, 2004.
DOI : 10.1097/01.ju.0000133560.87118.4d

C. Rogers, G. Yan, S. Zha, M. Gonzalgo, W. Isaacs et al., PROSTATE CANCER DETECTION ON URINALYSIS FOR ?? METHYLACYL COENZYME A RACEMASE PROTEIN, The Journal of Urology, vol.172, issue.4, pp.1501-1503, 2004.
DOI : 10.1097/01.ju.0000137659.53129.14

X. Wang, J. Yu, A. Sreekumar, S. Varambally, R. Shen et al., Autoantibody Signatures in Prostate Cancer, New England Journal of Medicine, vol.353, issue.12, pp.1224-1235, 2005.
DOI : 10.1056/NEJMoa051931

E. Leman, G. Cannon, B. Trock, L. Sokoll, D. Chan et al., RETRACTED: EPCA-2: A Highly Specific Serum Marker for Prostate Cancer, Urology, vol.69, issue.4, pp.714-720, 2007.
DOI : 10.1016/j.urology.2007.01.097

R. Nam, T. A. Klotz, L. Trachtenberg, J. Jewett, M. Loblaw et al., Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer, Can J Urol. Avr, vol.13, issue.2, pp.2-10, 2006.

G. Kost, Guidelines for point-of-care testing. Improving patient outcomes, Am. J. Clin. Pathol, vol.104, issue.4, pp.111-127, 1995.

F. Hobbs, B. Delaney, D. Fitzmaurice, S. Wilson, C. Hyde et al., A review of near patient testing in primary care, Health Technol Assess, vol.1, issue.5, pp.1-229, 1997.

A. Azzouzi, S. Larre, L. Cormier, M. Roupret, A. Valeri et al., Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer, BJU International, vol.57, issue.4, pp.762-764, 2007.
DOI : 10.1111/j.1464-410X.2006.06701.x

D. An, C. Yoshiki, T. Lee, G. Okada, and Y. , Evaluation of a rapid qualitative prostate specific antigen assay, the One Step PSA(TM) test. Cancer Lett, pp.135-139, 2001.

O. Karim, A. Rao, M. Emberton, D. Cochrane, M. Partridge et al., Point-of-care PSA testing: an evaluation of PSAwatch, Prostate Cancer and Prostatic Diseases, vol.92, issue.3, pp.270-273, 2007.
DOI : 10.1111/j.1464-410X.2003.04533.x

D. Kim, N. Lee, J. Park, I. Park, J. Kim et al., Organic electrochemical transistor based immunosensor for prostate specific antigen (PSA) detection using gold nanoparticles for signal amplification, Biosensors and Bioelectronics, vol.25, issue.11, 20435461.
DOI : 10.1016/j.bios.2010.04.013

Y. Lin, J. Wang, G. Liu, H. Wu, C. Wai et al., A nanoparticle label/immunochromatographic electrochemical biosensor for rapid and sensitive detection of prostate-specific antigen, Biosensors and Bioelectronics, vol.23, issue.11, pp.1659-1665, 2008.
DOI : 10.1016/j.bios.2008.01.037

S. Oh, Y. Kim, H. Kim, S. Kim, J. Cho et al., Point-of-care fluorescence immunoassay for prostate specific antigen, Clinica Chimica Acta, vol.406, issue.1-2, pp.18-22, 2009.
DOI : 10.1016/j.cca.2009.04.013